Meta-Analysis
doi: 10.3109/07357901003735634.
The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis
Affiliations
- PMID: 20394501
- DOI: 10.3109/07357901003735634
Item in Clipboard
Meta-Analysis
The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis
Cancer Invest.
2010 Jul.
Abstract
To evaluate the prognostic value of matrix metalloproteinase2 (MMP-2) expression in patients with non-small cell lung cancer (NSCLC), the electronic database PubMed, EMBASE were searched for relevant articles. The meta-analysis was finally based on 11 studies that included 1,439 patients, and combined HR was 1.66 (95% confidence intervals (CI: 1.37-2.01). Its effect also appeared significant when the analysis was restricted to tumor cell expression and patients with adenocarcinoma (HR 2.08 (95% CI: 1.24-3.48)). This study supported the fact that MMP-2 could be included in further prospective trials studying prognostic factors in NSCLC.
Similar articles
-
Prognostic Value of Expression of MicroRNAs in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.Clin Lab. 2016 Nov 1;62(11):2203-2211. doi: 10.7754/Clin.Lab.2016.160426. Clin Lab. 2016. PMID: 28164670
-
Chemotherapy for advanced non-small cell lung cancer in the elderly population.Sao Paulo Med J. 2016 Sep-Oct;134(5):465-466. doi: 10.1590/1516-3180.20161345T1. Sao Paulo Med J. 2016. PMID: 27901246 Free PMC article.
-
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.Cochrane Database Syst Rev. 2017 Dec 16;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2021 Dec 6;12:CD011300. doi: 10.1002/14651858.CD011300.pub3. PMID: 29247502 Free PMC article. Updated.
-
Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.J Clin Oncol. 2016 Sep 10;34(26):3204-12. doi: 10.1200/JCO.2015.66.3955. Epub 2016 Jul 18. J Clin Oncol. 2016. PMID: 27432922
-
Clinical relevance of the multidrug resistance‑associated protein 1 gene in non‑small cell lung cancer: A systematic review and meta‑analysis.Oncol Rep. 2018 Nov;40(5):3078-3091. doi: 10.3892/or.2018.6652. Epub 2018 Aug 17. Oncol Rep. 2018. PMID: 30132569
Cited by
-
Plasminogen Activator Inhibitor-2 Plays a Leading Prognostic Role among Protease Families in Non-Small Cell Lung Cancer.PLoS One. 2015 Jul 31;10(7):e0133411. doi: 10.1371/journal.pone.0133411. eCollection 2015. PLoS One. 2015. PMID: 26230665 Free PMC article.
-
Prognostic Role of Matrix Metalloproteinases in Cervical Cancer: A Meta-Analysis.Cancer Control. 2021 Jan-Dec;28:10732748211033743. doi: 10.1177/10732748211033743. Cancer Control. 2021. PMID: 34482737 Free PMC article.
-
Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.Oncol Res. 2017 Nov 2;25(9):1543-1553. doi: 10.3727/096504017X14886444100783. Epub 2017 Mar 8. Oncol Res. 2017. PMID: 28276313 Free PMC article.
-
SNAI2/SLUG and estrogen receptor mRNA expression are inversely correlated and prognostic of patient outcome in metastatic non-small cell lung cancer.BMC Cancer. 2015 Apr 17;15:300. doi: 10.1186/s12885-015-1310-1. BMC Cancer. 2015. PMID: 25928859 Free PMC article.
-
Blood Droplet-Based Cancer Diagnosis via Proteolytic Activity Measurement in Cancer Progression.Theranostics. 2017 Jul 8;7(11):2878-2887. doi: 10.7150/thno.19358. eCollection 2017. Theranostics. 2017. PMID: 28824722 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
